Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

Apr 07, 2020

SELL
$5.42 - $17.75 $108,400 - $355,000
-20,000 Closed
0 $0
Q1 2019

Apr 10, 2019

BUY
$1.97 - $2.57 $39,400 - $51,400
20,000 New
20,000 $46,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Silverleafe Capital Partners, LLC Portfolio

Follow Silverleafe Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverleafe Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverleafe Capital Partners, LLC with notifications on news.